Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Previously Treated Myelodysplastic Syndrome: early-phase trial registry
4 of 10 indexed Previously Treated Myelodysplastic Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Previously Treated Myelodysplastic Syndrome: 10 US clinical trials tracked, 4 recruiting.
Previously Treated Myelodysplastic Syndrome is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition previously-treated-myelodysplastic-syndrome
OPEN 4 | RECR 40% | LATE 0 | EARLY 10 | RANK #1724 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Previously Treated Myelodysplastic Syndrome lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Previously Treated Myelodysplastic Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Previously Treated Myelodysplastic Syndrome is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Previously Treated Myelodysplastic Syndrome research.
Fred Hutchinson Cancer Center accounts for 4 of 10 trials (40%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Previously Treated Myelodysplastic Syndrome enrolment sits around 127 participants.
Median target enrolment is 127 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.
-
Previously Treated Myelodysplastic Syndrome research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02115295
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT01624805
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT03017820
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
NCT02333162
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT02890329
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00105001
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT02044796
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Fred Hutchinson Cancer Center
NCT00027820
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
NCT02921061
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Brian Jonas
NCT02553941
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Previously Treated Myelodysplastic Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Previously Treated Myelodysplastic Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Previously Treated Myelodysplastic Syndrome page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Previously Treated Myelodysplastic Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Previously Treated Myelodysplastic Syndrome trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Previously Treated Myelodysplastic Syndrome condition card totals 10 registered trials; most-linked intervention Fludarabine Phosphate; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.